Intercept Plans To Refile OCA For NASH At US FDA With Consensus Reads Of Patient Biopsies
Executive Summary
Additional patients and more long-term data could also help make case for obeticholic acid. Intercept hopes to complete its review of the pivotal REGENERATE trial during H1 2022.
You may also be interested in...
Intercept Offloads Ex-US Business To Advanz, May Be Doubling Down On NASH In US
Still working to refile its NASH fibrosis NDA 22 months after an FDA complete response letter, Intercept gets $405m up front for its ex-US business, including commercial rights to Ocaliva in PBC.
Intercept Withdraws EU NASH Drug Filing But May Retry
New data that is being collected to support a US resubmission for Intercept’s obeticholic acid might also be used to support a resubmission to the European Medicines Agency.
Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs
CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.